Bildkälla: Stockfoto

Egetis Therapeutics: Short Comment on Capital Markets Day - Redeye

Redeye is encouraged by yesterday’s capital market day, which further emphasized that Egetis has a clear and derisked way to the market with lead project Emcitate. We give a short comment and will return with an updated view of the company within a month.

Redeye is encouraged by yesterday’s capital market day, which further emphasized that Egetis has a clear and derisked way to the market with lead project Emcitate. We give a short comment and will return with an updated view of the company within a month.
Börsvärldens nyhetsbrev
ANNONSER